Qube Research & Technologies (QRT)’s PetMed Express PETS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-13,315
Closed -$49K 3746
2024
Q3
$49K Sell
13,315
-44,100
-77% -$156K ﹤0.01% 2861
2024
Q2
$233K Sell
57,415
-41,234
-42% -$176K ﹤0.01% 2386
2024
Q1
$473K Sell
98,649
-257,247
-72% -$1.5M ﹤0.01% 2565
2023
Q4
$2.69M Buy
355,896
+125,694
+55% +$1.03M 0.01% 1384
2023
Q3
$2.36M Sell
230,202
-116,929
-34% -$1.44M 0.01% 1301
2023
Q2
$4.79M Buy
347,131
+334,161
+2,576% +$5.02M 0.02% 710
2023
Q1
$211K Sell
12,970
-67,186
-84% -$1.27M ﹤0.01% 1914
2022
Q4
$1.42M Buy
80,156
+65,952
+464% +$1.31M 0.01% 1068
2022
Q3
$277K Buy
+14,204
New +$302K ﹤0.01% 1657
2021
Q1
Sell
-12,630
Closed -$405K 2292
2020
Q4
$405K Buy
12,630
+5,191
+70% +$160K 0.01% 1224
2020
Q3
$235K Sell
7,439
-8,830
-54% -$292K ﹤0.01% 1342
2020
Q2
$580K Buy
16,269
+380
+2% +$13.2K 0.01% 1053
2020
Q1
$457K Buy
+15,889
New +$416K 0.02% 590

Other funds holding PETS

Qube Research & Technologies (QRT)'s PETS Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of PetMed Express (PETS) in Q4 2024, closing a stake of 13,315 shares — an estimated $49K sold.

Qube Research & Technologies (QRT) first reported a position in PETS in Q1 2020 and held it in 13 quarters. The position peaked at $4.79M in Q2 2023. 86 funds tracked by Wall St. Rank hold PETS as of Q4 2024.

  • Qube Research & Technologies (QRT) reported no remaining PetMed Express position as of Q4 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 13,315 PetMed Express shares in Q4 2024, an estimated $49K.
  • Qube Research & Technologies (QRT) first reported a position in PetMed Express in Q1 2020 and held it in 13 quarters.
  • Qube Research & Technologies (QRT)'s PetMed Express position peaked at $4.79M in Q2 2023.
  • 86 funds tracked by Wall St. Rank held PetMed Express as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.